๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hefei
Clinical trial register · China

Clinical Trials in Hefei, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Anhui Provincial Hospital55 Merck Sharp & Dohme LLC36 Anhui Medical University29 AstraZeneca27 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.25
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Hefei

875 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev
NCT04649489Venous Thrombosis
Jia Fan
Phase 3
501
Shanghai, Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei
2021-04-19
Active, closed
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
NCT04662255Lymphoma, Mantle-Cell
DrugsIbrutinib·Pirtobrutinib·Acalabrutinib·Zanubrutinib
Loxo Oncology, Inc.
Phase 3
500
Hefei, Beijing, Fuzhou, Guangzhou, Luoyang, Zhengzhou, Wuhan, Yichang
2021-04-08
Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
DrugNemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
490
Hefei, Beijing, Chongqing, Guangzhou, Liuzhou, Nanning, Zhengzhou, Wuhan
2021-04-05
Active, closed
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
NCT04544189Breast Neoplasms
Novartis Pharmaceuticals
Phase 2
69
Hefei, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Changsha, Nanjing
2021-01-20
Recruiting
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
NCT04649242Pediatric Migraine
Pfizer
Phase 3
2,100
Bengbu, Hefei, Beijing, Chongqing, Lanzhou, Shenzhen, Haikou, Shijiazhuang
2021-01-15
Active, closed
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
NCT04634877Endometrial Neoplasms
DrugsCisplatin·Carboplatin·Pembrolizumab·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
990
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Harbin, Wuhan
2021-01-10
Recruiting
Percutaneous Electrocoagulation Versus Sclerosing Foam for Patients With Incompetent Perforating Veins
NCT04686097Incompetent Perforating Veins
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
84
Hefei, Yantai, Shanghai, Hangzhou
2021-01-01
Recruiting
Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions.
NCT04688736Allergic Transfusion Reaction
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
6,642
Hefei, Zhoukou, Taiโ€™an, Tianjin
2021-01-01
Active, closed
Guo's Subclavian Artery Reconstruction: The Prospective, Multiple Center Study of WeFlow-Tbranch Stent Graft System(GUEST Study)
NCT04765605Type B Aortic Dissection
Hangzhou Endonom Medtech Co., Ltd.
Not applicable
120
Beijing, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Hangzhou, Hefei
2020-12-25
Recruiting
Secukinumab Open Label Roll-over Extension Protocol
NCT04638647Autoimmunity, Inflammation
DrugSecukinumab
Novartis Pharmaceuticals
Phase 4
1,000
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Shantou, Shenzhen, Wuhan
2020-12-22
Active, closed
Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
NCT04562766Immune Thrombocytopenia
DrugRilzabrutinib
Principia Biopharma, a Sanofi Company
Phase 3
232
Wuhan, Shenyang, Xi'an, Jinan, Tianjin, Kunming, Hangzhou, Hefei
2020-12-14
Recruiting
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
DrugsAdagrasib·Pembrolizumab
Mirati Therapeutics Inc.
Phase 2/3
626
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shenzhen
2020-12-02
Active, closed
Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
NCT04639986Metastatic Breast Cancer
DrugsEribulin mesylate·Vinorelbine·Sacituzumab Govitecan·Gemcitabine
Gilead Sciences
Phase 3
331
Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan
2020-11-23
Active, closed
Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
NCT04606433Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
47
Hefei, Beijing, Chongqing, Guangzhou, Changsha, Shanghai, Tianjin, Hangzhou
2020-11-04
Active, closed
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
NCT04581473Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsCT041 autologous CAR T-cell·Apatinib·Irinotecan
CARsgen Therapeutics Co., Ltd.
Phase 1/2
192
Hefei, Beijing, Fuzhou, Shenzhen, Harbin, Zhengzhou, Wuhan, Nanjing
2020-10-23
Active, closed
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
NCT04464226Cancer
DrugDarolutamide
Bayer
Phase 3
402
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Shenzhen
2020-10-20
Active, closed
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
NCT04524611Crohn's Disease (CD)
DrugsUstekinumab·Risankizumab
AbbVie
Phase 3
527
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Changsha
2020-09-30
Recruiting
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
NCT04685226Solid Tumors
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2
310
Hefei, Beijing, Guangzhou, Zhuhai, Guangdong, Shijiazhuang, Harbin, Luoyang
2020-09-27
Recruiting
Evaluate the Safety and Clinical Activity of HH2853
NCT04390737FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor
Haihe Biopharma Co., Ltd.
Phase 1/2
254
Hefei, Beijing, Guangzhou, Nanning, Zhengzhou, Wuhan, Changsha, Nanjing
2020-09-08
Recruiting
Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients
NCT06690970PSMA-related Disease, Prostate Cancer, Positron Emission Tomography, Metastasis
Tianjin Medical University
Observational
500
Hefei, Qingdao, Tianjin
2020-09-01
Active, closed
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
NCT04523272Advanced Renal Cancer
DrugsSunitinib·Anlotinib·Etoposide
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
528
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Harbin, Wuhan
2020-08-25
Active, closed
A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
NCT04344158Advanced Hepatocellular Carcinoma (HCC)
DrugAnlotinib hydrochloride
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
648
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Wuwei
2020-08-11
Active, closed
The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
NCT04233346Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
Otsuka Beijing Research Institute
Phase 2
93
Hefei, Guangzhou, Wuhan, Changsha, Suzhou, Shenyang, Jinan, Taiyuan
2020-07-09
Active, closed
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
NCT04232553Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
996
Hefei, Chongqing, Xiamen, Foshan, Guangzhou, Wuhan, Changsha, Changzhou
2020-06-22
Active, closed
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
NCT04379596Gastric Cancer
DrugsVolrustomig·Rilvegostomig·Trastuzumab deruxtecan·Trastuzumab
AstraZeneca
Phase 2
452
Chengdu, Guangzhou, Hefei, Shanghai, Shenyang, Wuhan, Zhengzhou
2020-06-03
Active, closed
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)
NCT04379635Non Small Cell Lung Cancer
BeiGene
Phase 3
453
Hefei, Beijing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Jiangmen, Shantou
2020-05-29
Active, closed
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
NCT04152499Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma
DrugSacituzumab tirumotecan
Klus Pharma Inc.
Phase 1/2
1,410
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou
2020-02-28
Active, closed
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
NCT04211337Medullary Thyroid Cancer
DrugsVandetanib·Selpercatinib·Cabozantinib
Loxo Oncology, Inc.
Phase 3
291
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Harbin, Zhengzhou
2020-02-11
Active, closed
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia
NCT04075292Untreated Chronic Lymphocytic Leukemia
AstraZeneca
Phase 3
155
Beijing, Changchun, Changsha, Changzhou, Guangzhou, Guiyang, Hangzhou, Hefei
2020-01-20
Active, closed
A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
NCT04165317Non-muscle Invasive Bladder Cancer
DrugBacillus Calmette-Guerin
Pfizer
Phase 3
1,068
Hefei, Beijing, Fuzhou, Wuhan, Changsha, Nanjing, Nantong, Suzhou
2019-12-30
Active, closed
A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
NCT04194775Hepatocellular Carcinoma
DrugLenvatinib
CStone Pharmaceuticals
Phase 3
534
Bengbu, Hefei, Beijing, Fuzhou, Xiamen, Foshan, Guangzhou, Nanning
2019-12-13
Recruiting
Segmentectomy Versus Lobectomy for Lung Adenocarcinoma โ‰ค 2cm
NCT04937283Lung Adenocarcinoma
Shanghai Pulmonary Hospital, Shanghai, China
Not applicable
690
Hefei, Nanyang, Nantong, Xuzhou, Yancheng, Jinan, Shanghai, Hangzhou
2019-10-01
Recruiting
Pan Tumor Rollover Study
NCT03899155Cancer
DrugsRucaparib·Relatlimab·Sunitinib·Cabozantinib
Bristol-Myers Squibb
Phase 2
1,500
Hefei, Beijing, Guangzhou, Harbin, Changsha, Nanjing, Changchun, Xi'an
2019-08-09
Active, closed
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
NCT04008030Metastatic Colorectal Cancer
DrugsIpilimumab·Leucovorin·Irinotecan·Nivolumab
Bristol-Myers Squibb
Phase 3
839
Hefei, Xiamen, Zhangzhou, Lanzhou, Foshan, Guangzhou, Nanning, Harbin
2019-08-05
Active, closed
Quantitative Flow Ratio (QFR) Guided Coronary Artery Bypass Grafting for Patients Undergoing Primary Valve Surgery With Concomitant Coronary Artery Disease
NCT03977129Primary Valvular Heart Disease With Comorbid Coronary Artery Disease, Planned to Undergo Elective On-pump Valve Surgery Due to Primary Mitral and/or Aortic Valvular Heart Disease
Ruijin Hospital
Not applicable
792
Hefei, Fuzhou, Zhengzhou, Changsha, Jinan, Qingdao, Shanghai, Tianjin
2019-08-04
Recruiting
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
NCT04270591C-Met Exon 14 Mutation
DrugGlumetinib
Haihe Biopharma Co., Ltd.
Phase 1/2
183
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Haikou, Harbin, Zhengzhou
2019-07-15
Active, closed
A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies
NCT03913949Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
Ascentage Pharma Group Inc.
Phase 1
74
Hefei, Zhengzhou, Wuhan, Tianjin, Hangzhou
2019-06-03
Active, closed
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
NCT03967977Urothelial Carcinoma
DrugsGemcitabine Hydrochloride·Cisplatin·Carboplatin·Tislelizumab
BeiGene
Phase 3
420
Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Harbin
2019-05-29
Recruiting
An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia
NCT03813407Hyperkalaemia
DrugPumitamig
AstraZeneca
Phase 3
140
Beijing, Changsha, Chengdu, Chongqing, Hangzhou, Hefei, Shanghai
2019-04-02
Active, closed
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
NCT03833154Carcinoma, Non-Small-Cell Lung
DrugDurvalumab
AstraZeneca
Phase 3
724
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Hangzhou, Hefei, Jinan
2019-03-06
Recruiting
Somatostatin Receptor PET/CT in SSTR-Related Disease Patients
NCT06690957SSTR-related Disease, Tumor, Positron Emission Tomography, Metastasis
Tianjin Medical University
Observational
500
Hefei, Qingdao, Tianjin
2019-02-01
Recruiting
Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease
NCT06725693GLP1-R-related Disease, Tumor, Insulinoma, Positron Emission Tomography
Tianjin Medical University
Observational
500
Hefei, Qingdao, Tianjin
2019-02-01
Recruiting
S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC๏ผ‰
NCT03941561Gastric Cancer
Fudan University
Phase 3
1,006
Anqing, Hangzhou, Hefei, Nanchang, Shanghai, Wuhu
2019-01-01
Recruiting
Liver Volume Metrics for Predicting Immunotherapy Prognosis in Unresectable Hepatocellular Carcinoma
NCT07782632Hepatocellular Carcinoma (HCC)
Anhui Provincial Hospital
Observational
467
Hefei
2019-01-01
Active, closed
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
NCT03734029Breast Cancer
DrugsEribulin·Trastuzumab deruxtecan·Nab-paclitaxel·Capecitabine
Daiichi Sankyo
Phase 3
557
Hefei, Beijing, Fuzhou, Guangzhou, Harbin, Wuhan, Nanjing, Changchun
2018-12-27
Active, closed
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
NCT03800134Non-Small Cell Lung Cancer
DrugsDurvalumab·Gemcitabine·Pemetrexed·Cisplatin
AstraZeneca
Phase 3
825
Beijing, Changsha, Changzhou, Chengdu, Guangzhou, Guiyang, Hangzhou, Hefei
2018-12-06
Active, closed
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
NCT03706365Prostate Cancer
DrugsAbiraterone acetate·Abemaciclib·Prednisone
Eli Lilly and Company
Phase 2/3
393
Hefei, Wuhu, Lanzhou, Guangzhou, Harbin, Luoyang, Wuhan, Changsha
2018-11-26
Recruiting
Translocator Protein PET/CT in Various TSPO-Related Disease
NCT06725719Neuroinflammation, Stroke, Neurodegenerative Diseases
Tianjin Medical University
Observational
200
Hefei, Qingdao, Tianjin
2018-11-01
Active, closed
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
NCT03539536Non-small Cell Lung Cancer
DrugTelisotuzumab vedotin
AbbVie
Phase 2
270
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Baoding, Harbin, Zhengzhou
2018-10-10
Recruiting
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
NCT03736889MSI-H/dMMR Solid Tumors
BeiGene
Phase 2
200
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Huizhou, Meizhou, Hechi
2018-09-19
Active, closed
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
NCT03398135Ulcerative Colitis (UC)
DrugRisankizumab
AbbVie
Phase 3
1,242
Hefei, Beijing, Guangzhou, Shijiazhuang, Wuhan, Changsha, Huaian, Nanjing
2018-08-28
Recruiting
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
NCT03486873Solid Tumors, Hematologic Malignancies
Drugs) Berahyaluronidase alfa·Olaparib·Lenvatinib·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
3,500
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guanghzou, Guangzhou, Guiyang
2018-08-21
Recruiting
Tau PET/CT in Various Tau-Related Disease Patients
NCT06690983Tauopathies, Neurodegenerative Diseases, Neurodegeneration
Tianjin Medical University
Observational
500
Hefei, Qingdao, Tianjin
2018-08-01
Active, closed
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
NCT03519945Ulcerative Colitis
DrugMirikizumab
Eli Lilly and Company
Phase 3
1,058
Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei
2018-07-18
Active, closed
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
NCT03504397Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsFolinic acid·Zolbetuximab·Oxaliplatin·Bevacizumab
Astellas Pharma Global Development, Inc.
Phase 3
565
Haerbin, Nanjing, Hangzhou, Beijing, Hefei, Xiamen, Zhengzhou
2018-06-21
Active, closed
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
NCT03755791Hepatocellular Carcinoma
DrugsSorafenib·Cabozantinib·Atezolizumab
Exelixis
Phase 3
837
Hefei, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing
2018-06-10
Active, closed
Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer
NCT03519230Ovarian Cancer
DrugPamiparib
BeiGene
Phase 3
224
Hefei, Beijing, Chongqing, Guangzhou, Shantou, Nanning, Harbin, Zhengzhou
2018-05-14
Active, closed
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
NCT03395197mCRPC
Pfizer
Phase 3
1,054
Hefei, Beijing, Fuzhou, Xiamen, Wuhan, Lianyungang, Nanjing, Nantong
2017-12-18
Active, closed
Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy
NCT03315364Recurrent or Metastatic Breast Cancer
DrugsTaxol·Paclitaxel
Daehwa Pharmaceutical Co., Ltd.
Phase 2/3
549
Hefei, Beijing, Guangzhou, Haikou, Harbin, Zhengzhou, Nanjing, Changchun
2017-12-18
Active, closed
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
NCT03336333Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsBendamustine·Zanubrutinib·Venetoclax·Rituximab
BeiGene
Phase 3
590
Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Guangzhou, Zhengzhou, Wuhan
2017-10-31
Active, closed
A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation
NCT03182244AML With FLT3 Mutation
Astellas Pharma Inc
Phase 3
276
Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei
2017-10-25
Active, closed
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT02966756Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
DrugVenetoclax
AbbVie
Phase 2
66
Hefei, Beijing, Fuzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha
2017-10-12
Active, closed
Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis
NCT03221036Moderately to Severely Active Ulcerative Colitis
DrugVedolizumab
Takeda
Phase 3
392
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Zhangzhou, Guangzhou, Meizhou
2017-08-03
Active, closed
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
NCT03164616Non Small Cell Lung Cancer NSCLC
DrugsAbraxane·Tremelimumab·Durvalumab·Gemcitabine
AstraZeneca
Phase 3
1,186
Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei
2017-06-01
Active, closed
Durvalumab ยฑ Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)
NCT03043872Small Cell Lung Carcinoma Extensive Disease
DrugsTremelimumab·Etoposide·Durvalumab·Cisplatin
AstraZeneca
Phase 3
987
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Hangzhou, Hefei
2017-03-27
Recruiting
Multimodal Survival Prediction Model for Colorectal Liver Metastases Post-Operation
NCT07830576Colorectal Liver Metastases, Colorectal Neoplasms, Liver Neoplasms
Anhui Provincial Hospital
Observational
205
Hefei
2017-02-01
Active, closed
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
NCT02864992Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
EMD Serono Research & Development Institute, Inc.
Phase 2
337
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei
2016-09-13
Active, closed
eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
NCT02767804Non-small Cell Lung Cancer
DrugsEnsartinib·Crizotinib
Xcovery Holdings, Inc.
Phase 3
290
Hefei, Beijing, Fuzhou, Guangzhou, Shijiazhuang, Changsha, Wuhan, Nanjing
2016-06
Active, closed
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
NCT02609776Non-Small-Cell Lung Cancer
DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin
Janssen Research & Development, LLC
Phase 1
751
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei
2016-05-24
Active, closed
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
NCT02486718Non-Small Cell Lung Cancer
DrugsVinorelbine·Atezolizumab·Gemcitabine·Pemetrexed
Hoffmann-La Roche
Phase 3
1,280
Beijing, Guangzhou, Hangzhou, Hefei, Shanghai, Shengyang, Shenyang, Suzhou
2015-10-31
Active, closed
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
NCT02152631Non Small Cell Lung Cancer
DrugsErlotinib·Abemaciclib
Eli Lilly and Company
Phase 3
453
Beijing, Changchun, Changzhou, Chengdu, Haikou, Hangzhou, Hefei, Nanning
2014-10-03
Recruiting
Amino Acid Transporter System PET/CT Imaging in AATS-Related Diseases
NCT07379463Amino-Acid Transport Disorder, Primary Hyperparathyroidism, Glioma
Tianjin Medical University
Observational
500
Hefei, Qingdao, Tianjin
2013-08-29
Recruiting
Beta Amyloid PET/CT in Various Aฮฒ-Related Disease
NCT06725706Amyloid, Beta-Amyloid, Neurodegenerative Diseases
Tianjin Medical University
Observational
500
Hefei, Beijing, Qingdao, Tianjin
2012-09-01
Recruiting
The Chinese Familial Alzheimer's Network
NCT03657732Alzheimer Disease, Familial Alzheimer Disease (FAD)
Capital Medical University
Observational
40,000
Hefei, Changping, Chaoyang, Fengtai, Haidian, Xicheng, Yuzhong, Fujian
2005-01-10
Recruiting
China Cognition and Aging Study
NCT03653156Mild Cognitive Impairment(MCI), Alzheimer Disease, Late Onset, Familial Alzheimer Disease (FAD), Vascular Dementia (VaD)
Capital Medical University
Observational
100,000
Hefei, Changping, Chaoyang, Fengtai, Haidian, Xicheng, Yuzhong, Fujian
2000-01-01
Rows per page Showing 801–875 of 875
Previous 7 8 9
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/hefei?page=9

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 875 of those studies with a site in Hefei.

How many clinical trials are recruiting in Hefei?

512 of the 875 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 137 have not yet opened recruitment, 211 are active but closed to new participants, and 15 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.